The effect of PGA1 on the immune response in B-16 melanoma-bearing mice

Prostaglandins
C FavalliB M Jaffe

Abstract

This study evaluated the effects of PGA1 on B-16 melanoma-bearing mice. Intraperitoneal injection of PGA1 (10 microgram/day) significantly inhibited the rate of melanoma growth measured both as delay in the rate of appearance and decrease in the tumor volume. In contrast to the diluent control-treated mice, by 17 days, less than half of the PGA1-treated animals developed measurable (greater than 2 mm) subcutaneous tumors. In addition to its effect on tumor size, PGA1 was also effective in stimulating both the humoral and cellular components of the immune response. B-16 tumor-bearing mice were shown to be immunosuppressed, in that they had decreased anti-sRBC hemagglutinin titers, decreased splenic plaque-forming cells, suppressed delayed hypersensitivity responses, and delayed rejection of skin allografts from BALB/c mice. Although, PGA1 had relatively little effect on normal mice, this prostaglandin substantially improved all these immunologic parameters in tumor-bearing animals.

References


❮ Previous
Next ❯

Citations

Jul 1, 1991·Diseases of the Colon and Rectum·A YamaguchiI Miyazaki
Jun 1, 1982·The Journal of Surgical Research·D HoferB M Jaffe
Sep 1, 1983·Prostaglandins·M D Bregman, F L Meyskens
Jan 1, 1992·International Journal of Immunopharmacology·Y KikuchiM Fukushima
Jan 1, 1988·General Pharmacology·K SuzukiH Suzuki
Oct 1, 1982·New Zealand Veterinary Journal·G W HornerA M Day
Mar 21, 2006·Biochemistry. Biokhimii︠a︡·A I Hubich, M V Sholukh
Dec 1, 1994·Cancer Metastasis Reviews·Y KikuchiM Fukushima
Jan 1, 1992·Journal of Cancer Research and Clinical Oncology·I KlapanV Cuk
Jan 1, 1984·International Journal of Immunopharmacology·N O OlssonF Martin
Aug 11, 1991·The Journal of Surgical Research·M P KahkyH V Gaskill
Aug 31, 1982·Biochemical and Biophysical Research Communications·M G SantoroA Benedetto
Oct 1, 1988·Current Problems in Surgery·B M JaffeK Kimura
Dec 30, 1986·Biochemical and Biophysical Research Communications·E GouinF Dray
Feb 11, 1982·Biochemical and Biophysical Research Communications·M D BregmanF L Meyskens
Jan 1, 1989·Immunopharmacology and Immunotoxicology·S D'AtriA Giuliani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.